SNTI Senti Biosciences, Inc.

Nasdaq sentibio.com


$ 2.16 $ 0.06 (2.86 %)    

Friday, 17-Oct-2025 15:27:21 EDT
QQQ $ 604.24 $ 6.63 (1.11 %)
DIA $ 462.26 $ 2.90 (0.63 %)
SPY $ 664.61 $ 5.14 (0.78 %)
TLT $ 91.14 $ -0.09 (-0.1 %)
GLD $ 388.98 $ -8.20 (-2.06 %)
$ 2.18
$ 2.13
$ 2.16 x 421
$ 2.18 x 11
$ 2.11 - $ 2.18
$ 1.26 - $ 16.94
404,581
na
57.03M
$ 2.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-07-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 07-02-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-initiates-coverage-on-senti-biosciences-with-buy-rating-announces-price-target-of-12

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Buy rating and ann...

 senti-bio-highlights-phase-2-dose-selection-for-senti-202-car-nk-therapy-in-virtual-investor-segment

Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation ...

 chardan-capital-maintains-buy-on-senti-biosciences-maintains-12-price-target

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and maintains $12 price target.

 senti-biosciences-q2-eps-056-beats-090-estimate

Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0...

 senti-bios-experimental-cancer-treatment-gets-fda-boost-for-targeting-deadly-leukemia

Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company de...

 senti-biosciences-gets-fda-orphan-drug-designation-for-senti-202-for-treatment-of-acute-myeloid-leukemia

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1078725

 chardan-capital-maintains-buy-on-senti-biosciences-maintains-12-price-target

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and maintains $12 price target.

 laidlaw--co-initiates-coverage-on-senti-biosciences-with-buy-rating-announces-price-target-of-15

Laidlaw & Co. analyst Yale Jen initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Buy rating and announces Pri...

 senti-bio-announces-it-has-received-additional-1m-tranche-from-california-institute-for-regenerative-medicines-grant-for-advancing-clinical-development-of-senti-202

Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company de...

 senti-biosciences-announces-release-of-its-new-animated-video-for-its-lead-asset-in-development-senti-202-cell-therapy-product-candidate-designed-to-selectively-target-and-eliminate-cd33-andor-flt3-expressing-hematologic-malignancies

Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company de...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION